V. Guillem

J. Carles, V. Guillem, J. Bellmunt, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature

M. Climent, V. Guillem, E. Esteban, 2015, BMC Urology.

36th annual San Antonio Breast Cancer Symposium. Resumen de lo más destacado

M. Climent, V. Guillem, A. Guerrero, 2014 .

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma – Prima study

J. Malvehy, V. Guillem, E. Espinosa, 2016, Melanoma research.

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.

A. Ruíz, V. Guillem, N. Ribelles, 2007, The Lancet. Oncology.

Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.

J. Garcia-conde, A. Lluch, V. Guillem, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.

I. Marugán, V. Guillem, B. Bellosillo, 2012, Blood.

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

J. Baselga, J. J. de la Cruz, J. Carles, 2002, Cancer.

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

J. Baselga, J. J. de la Cruz, J. Carles, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.

V. Guillem, L. Paz-Ares, E. Esteban, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of UFT activity in pretreated breast cancer patients.

J. Garcia-conde, V. Guillem, C. Herranz, 1993, Japanese journal of clinical oncology.

The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support

M. Climent, A. Ruíz, V. Guillem, 1998, Supportive Care in Cancer.

Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.

I. Marugán, V. Guillem, J. Cervera, 2012, Leukemia research.

BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia.

V. Guillem, C. Solano, P. Eroles, 2015, Leukemia research.

Epidermal growth factor in human breast cancer, endometrial carcinoma and lung cancer. Its relationship to epidermal growth factor receptor, estradiol receptor and tumor TNM.

J. Garcia-conde, A. Lluch, V. Guillem, 1993, Clinica chimica acta; international journal of clinical chemistry.

Risk factors for non‐melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera

V. Guillem, Arturo Pereira, J. Martínez-López, 2016, European journal of haematology.

Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.

A. Lluch, V. Guillem, V. Carañana, 2000, Seminars in oncology.

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

J. Baselga, J. J. de la Cruz, J. Carles, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Germ cell tumours of the ovary

V. Guillem, A. Poveda, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.

A. Tres, J. Mayordomo, V. Guillem, 2001, Journal of the National Cancer Institute.

Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice

M. Climent, A. Ruíz, V. Guillem, 2015, International Journal of Clinical Oncology.

Clinical practice guidelines on antiemetics in oncology

V. Guillem, H. Cortés-Funes, E. Aguilar, 2005, Expert review of anticancer therapy.

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

M. Climent, A. Llombart‐Bosch, A. Guerrero-Zotano, 2010, BMC Cancer.

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

M. Piccart, J. Baselga, P. Gascón, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study

A. Ruíz, A. Lluch, V. Guillem, 2015, PloS one.

Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case–control EpiGEICAM study

A. Ruíz, A. Lluch, V. Guillem, 2014, British Journal of Cancer.

Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern Similarity.

A. Ruíz, A. Lluch, V. Guillem, 2016, Journal of the Academy of Nutrition and Dietetics.

Specific oncological contribution of cathepsin D and pS2 in human breast cancer: their relationship with TNM status, estradiol receptors, epidermal growth factor receptor and neu amplification.

V. Guillem, J. A. Lopez, B. Munárriz, 1996, Clinica chimica acta; international journal of clinical chemistry.

Phase I study of mitonafide in solid tumors

A. Ruíz, V. Guillem, V. Soriano, 1992, Investigational New Drugs.

Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain.

V. Guillem, M. Casado, M. Álvarez-Mon, 2000, European journal of cancer.

LAS 30451: a novel 5-HT3 antagonist.

V. Guillem, V. Soriano, M. Martín, 1993, European journal of cancer.

Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies

J. Esteve, M. Tormo, M. Terol, 2007, Leukemia.

440 Superiority of tandem high-dose (HDC) over conventionally-dosed chemotherapy(CDC) in patients (Pts) with metastatic breast cancer (MBC): Updated results of the international randomised breast cancer dose-intensity study (IBDIS)

J. Baselga, V. Guillem, S. Leyvraz, 2003 .

Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper

V. Guillem, V. Jiménez‐Yuste, Á. Rodríguez-Lescure, 2022, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts

A. Carrato, P. Gascón, V. Guillem, 2019, Journal of pain research.

[Experience in the treatment of 98 carcinomas of the nasopharynx. Long-term follow-up and analysis of prognostic factors].

M. Climent, E. Zapater, V. Guillem, 2000, Acta otorrinolaringologica espanola.

Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.

J. Moul, C. Sternberg, V. Guillem, 2008, Critical reviews in oncology/hematology.

APC and KRAS mutations in distal colorectal polyps are related to smoking habits in men: results of a cross-sectional study

V. Guillem, F. Dasí, A. Castells, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status.

A. Ruíz, A. Lluch, V. Guillem, 1997, Clinica chimica acta; international journal of clinical chemistry.

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

K. Hutchinson, S. Michiels, A. Guerrero-Zotano, 2018, Clinical Cancer Research.

Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique.

A. Carrato, J. Albanell, A. Lluch, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

European edition of the NCCN clinical practice guidelines: relevance of the translation and adaptation into Spanish

A. Carrato, P. Gascón, V. Guillem, 2017, Clinical and Translational Oncology.

Randomized comparison of broad spectrum antibiotics with or without filgrastim in the treatment of patients with high-risk fever and grade IV neutropenia

J. Mayordomo, V. Guillem, L. Paz-Ares, 1999 .

First-line phase II trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment

J. Carles, V. Guillem, J. Bellmunt, 2007 .

Delphi Consensus on the Follow-up of Cancer Patients with Breakthrough Pain Under Opioid Treatment

V. Guillem, C. Camps, O. Fernández Calvo, 2019, SN Comprehensive Clinical Medicine.

Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)

J. Baselga, M. Climent, A. Lluch, 2004 .

Gene expression profiling (GEP) for the prediction of response to neoadjuvant paclitaxel and gemcitabine in breast cancer (BC). Preliminary results from a Phase II trial.

J. Mayordomo, J. Albanell, A. Ruíz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

responding The

V. Guillem, L. Paz-Ares, R. Rosell, 2010 .

Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.

J. Moul, C. Sternberg, V. Guillem, 2008, Critical reviews in oncology/hematology.

This is the peer reviewed version of the following article: Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern Similarity

A. Ruíz, A. Lluch, V. Guillem, 2019 .

Cost-effectiveness of interferon for high-risk (stage III) melanoma patients

V. Guillem, J. González-Larriba, J. Toribio, 1999 .

Response to neoadjuvant chemotherapy and outcome based on breast cancer subtype.

M. Climent, A. Guerrero-Zotano, A. Ruíz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.